Vertex Pharmaceuticals (VRTX) R&D In Process (2021 - 2025)
Vertex Pharmaceuticals (VRTX) has 5 years of R&D In Process data on record, last reported at $2.2 million in Q2 2025.
- For Q2 2025, R&D In Process fell 99.95% year-over-year to $2.2 million; the TTM value through Jun 2025 reached $122.0 million, down 97.33%, while the annual FY2025 figure was $133.0 million, 97.11% down from the prior year.
- R&D In Process reached $2.2 million in Q2 2025 per VRTX's latest filing, down from $19.8 million in the prior quarter.
- Across five years, R&D In Process topped out at $4.4 billion in Q2 2024 and bottomed at $2.0 million in Q1 2022.
- Average R&D In Process over 5 years is $320.5 million, with a median of $46.3 million recorded in 2023.
- Peak YoY movement for R&D In Process: surged 3902.9% in 2024, then crashed 99.95% in 2025.
- A 5-year view of R&D In Process shows it stood at $113.2 million in 2021, then plummeted by 80.04% to $22.6 million in 2022, then decreased by 21.24% to $17.8 million in 2023, then skyrocketed by 232.02% to $59.1 million in 2024, then crashed by 96.28% to $2.2 million in 2025.
- Per Business Quant database, its latest 3 readings for R&D In Process were $2.2 million in Q2 2025, $19.8 million in Q1 2025, and $59.1 million in Q4 2024.